SCHEMBL6860540

SCHEMBL6860540

COc1ccc2c(c1)cc(-c1cccc(OC)c1-c1cc3cc(OC)ccc3n1S(=O)(=O)c1ccccc1)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ACLY P53396 1/20 0.47
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GRIK1 P39086 1/20 0.43
GRIK2 Q13002 1/20 0.43
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866369 0.85 HTR6 (0.47) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL3561484 0.81 ACLY (0.65) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL16638211 0.80 HTR6 (0.51) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL9737717 0.78 HTR6 (0.60) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL3686412 0.77 CA12 (0.50) HTR6POLBL3MBTL1MEN1KMT2A
SCHEMBL3555665 0.77 HTR6 (0.63) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL28016373 0.75 ACLY (0.60) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL6867966 0.74 HTR6 (0.48) HTR6POLBL3MBTL1HDAC3HDAC4
SCHEMBL9737236 0.74 HTR6 (0.43) HTR6POLBL3MBTL1ACLYHDAC3
SCHEMBL6860260 0.74 HTR6 (0.59) HTR6POLBL3MBTL1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812243-B2 AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES ZENTARIS AG (DE) 2004-11-02 US disclosed
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation ZENTARIS AG (DE) 2003-01-09 US disclosed
US-6407102-B1 TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS ZENTARIS AG (DE) 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation MKI67, IDO1, CCNI HTR6 265/4885POLB 2321/4885L3MBTL1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.